On or around 01/31/2017 (Other)
Filing Date: July 31, 2014
According to the law firm press release, the Complaint alleges that the Defendants made false and misleading statements about the FDA’s approval of a clinical trial and the time for completion of the trial and submission of data to the FDA. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act.
According to the docket entry made on October 7, 2014, the Court entered an electronic Order appointing lead plaintiff and lead counsel. Lead Plaintiff filed a Complaint on October 30.
On April 3, 2015, the Court issued an Order dismissing and closing this case.
Company & Securities Information
Defendant: InVivo Therapeutics Holdings Corp.
Industry: Medical Equipment & Supplies
Headquarters: United States
Ticker Symbol: NVIV
Company Market: OTC-BB
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Battle Construction Co., Inc., et al. v. InVivo Therapeutics Holdings Corp., et al.